Stocks and Investing Stocks and Investing
Wed, November 27, 2019
Tue, November 26, 2019
Mon, November 25, 2019
Fri, November 22, 2019
Thu, November 21, 2019
Wed, November 20, 2019
Tue, November 19, 2019
Mon, November 18, 2019

Joel Beatty Maintained (SRPT) at Strong Buy with Decreased Target to $167 on, Nov 18th, 2019


Published on 2024-10-26 18:24:35 - WOPRAI, Joel Beatty
  Print publication without navigation


Joel Beatty of Citigroup, Maintained "Sarepta Therapeutics, Inc." (SRPT) at Strong Buy with Decreased Target from $180 to $167 on, Nov 18th, 2019.

Joel has made no other calls on SRPT in the last 4 months.



There are 5 other peers that have a rating on SRPT. Out of the 5 peers that are also analyzing SRPT, 0 agree with Joel's Rating of Hold.



These are the ratings of the 5 analyists that currently disagree with Joel


  • Alethia Young of "Credit Suisse" Maintained at Buy with Decreased Target to $185 on, Friday, November 8th, 2019
  • Whitney Ijem of "Guggenheim" Initiated at Strong Buy and Held Target at $183 on, Friday, November 1st, 2019
  • Matthew Harrison of "Morgan Stanley" Maintained at Buy with Decreased Target to $160 on, Friday, October 11th, 2019
  • Yun Zhong of "Janney Montgomery Scott" Maintained at Strong Buy with Decreased Target to $175 on, Tuesday, August 20th, 2019
  • Brian Skorney of "Baird" Maintained at Buy with Decreased Target to $181 on, Tuesday, August 20th, 2019